Patent · US Active

Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof

US10646488B2 · kind B2 · utility

18Cited by
64References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 13, 2017
Grant dateMay 12, 2020
Priority date—
Expiry dateJul 13, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/545
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.